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Abstract
The majority of ovarian tumors eventually recur in a drug resistant form. Using cisplatin sen-
sitive and resistant cell lines assembled into 3D spheroids we profiled gene expression and
identified candidate mechanisms and biological pathways associated with cisplatin resis-
tance. OVCAR-8 human ovarian carcinoma cells were exposed to sub-lethal concentra-
tions of cisplatin to create a matched cisplatin-resistant cell line, OVCAR-8R. Genome-wide
gene expression profiling of sensitive and resistant ovarian cancer spheroids identified
3,331 significantly differentially expressed probesets coding for 3,139 distinct protein-cod-
ing genes (Fc >2, FDR < 0.05) (S2 Table). Despite significant expression changes in some
transporters including MDR1, cisplatin resistance was not associated with differences in
intracellular cisplatin concentration. Cisplatin resistant cells were significantly enriched for a
mesenchymal gene expression signature. OVCAR-8R resistance derived gene sets were
significantly more biased to patients with shorter survival. From the most differentially
expressed genes, we derived a 17-gene expression signature that identifies ovarian cancer
patients with shorter overall survival in three independent datasets. We propose that the
use of cisplatin resistant cell lines in 3D spheroid models is a viable approach to gain insight
into resistance mechanisms relevant to ovarian tumors in patients. Our data support the
emerging concept that ovarian cancers can acquire drug resistance through an epithelial-
to-mesenchymal transition.
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Introduction
High Grade Serous Ovarian Cancer (HGSOC) is the most lethal form of ovarian cancer with
approximately 16,000 new cases in the United States each year with 5 year survival rates<30%
[1]. Platinum and taxane-based chemotherapy are the most common first-line agents, however,
eventual resistance to cisplatin and recurrence of ovarian cancer following initial therapy is a
major limitation [2], and is associated with poor prognosis following recurrence [3]. Thus,
there is a pressing medical need to identify predictive markers in order to identify patients who
will benefit from chemotherapy, and to develop new treatment options for this lethal disease.
Myriad mechanisms of platinum therapy resistance have been identified including changes
in cisplatin transport and trafficking, disruption of apoptosis, increased tolerance of cisplatin-
DNA adducts, and increased DNA repair in response to cisplatin-DNA interactions [4, 5].
Many tumors exhibit multiple resistance pathways simultaneously [6].
Experimental models have not recapitulated the many features exhibited in tumors includ-
ing intercellular communication and the influence of the microenvironment [7]. There has
been increasing interest in 3D culture models amenable for high-throughput screening [7, 8].
We aimed to characterize a spheroid cisplatin resistance model and determine how well this
model recapitulates resistance mechanisms observed in patients. Moreover, more in vitro mod-
els are needed to model the extensive heterogeneity of HGSOC [7]. Other recently derived
resistant models such as SKOV3 [9] may not be good models of HGSOC, [10] leaving just
OVCAR3 as a potential model[11].
Towards these goals, we derived a new OVCAR-8 cisplatin resistant cell line (OVCAR-8R)
and used genome wide expression analysis to discover genes differentially expressed in the sen-
sitive and resistant cells as spheroids. Genes differentially expressed between the parental and
resistant OVCAR-8 cells are enriched for markers of the mesenchymal state and are associated
with survival. Despite significant expression changes of cisplatin transporters, OVCAR-8R
spheroids did not show significantly different intracellular platinum concentration or transport
properties compared to the parental OVCAR-8 spheroids. We applied multiple methods to
evaluate how similar the expression changes adapted by OVCAR-8R may be reflected in
HGSOC tumors. A pathway and a direct evaluation of a set of genes both indicated that
many features of OVCAR-8R spheroids model HGSOC tumors. These data indicate that the
OVCAR-8R spheroid model captured critical aspects of cisplatin resistance relevant to ovarian
cancer patients.
Materials and Methods
Reagents
Cisplatin (cis-diamminedichloroplatinum(II)) was purchased from Sigma-Aldrich.
The human ovarian adenocarcinoma cancer cell line OVCAR-8 cell line was purchased
through the National Cancer Institute Developmental Therapeutics Program’s tumor reposi-
tory program. OVCAR-8 was made resistant in vitro by continuous stepwise exposure to cis-
platin up to 5 μM to produce the corresponding cisplatin-resistant cell line OVCAR-8R. The
cells were stably resistant after 6 weeks of growth in the absence of cisplatin. All cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Grand Island, NY) con-
taining 10% fetal bovine serum (FBS) with antibiotics (50 units penicillin/mL DMEM, 50 μg
streptomycin/mL). Cells were grown as attached monolayers and incubated in a humidified
atmosphere with 5% CO2 at 37°C. OVCAR-8 cell lines were authenticated by the ATCC Cell
Line Authentication Service.
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Cell viability assay
Cells were plated in 96 well plates and treated 24 h later with the indicated concentrations of
cisplatin. Viability was measured after 96 h of treatment using the WST-1 reagent (Roche),
according to the manufacturer’s instructions.
Spheroid generation
Spheroids were generated by seeding OVCAR-8 and OVCAR-8R cells in low attachment aga-
rose gel molds with hemispherical recesses. Gel casts were created by pouring 2% agarose into
3D Petri Dish casting molds (Microtissues, Providence, RI) [12, 13]. To generate spheroids
with a diameter of about 300 μm, approximately 10,000–25,000 cells in 190 μL DMEM were
placed in each mold and allowed to grow for 2–3 days before collection.
Cisplatin uptake assay
Net cisplatin uptake was determined by measuring platinum content of ovarian cancer cells
before and after incubation with cisplatin. Equal numbers of OVCAR-8 and OVCAR-8R cells
were plated in T75 flasks. Cells were treated with 5 μM cisplatin for 3 hrs. After cisplatin treat-
ment, cells were washed once with HBSS, and then with PBS lacking calcium and magnesium.
Cells were then dissociated in PBS containing no calcium or magnesium and containing 5 mM
EDTA, and centrifuged at 229 x g. The pellet was dissolved in 20 mM Tris, pH 7.6 and the cells
lysed by multiple freeze-thaw cycles at -80°C.
Platinum was measured by using an Agilent 7500CE ICP-MS (Agilent Technologies, Palo
Alto, CA) at the Interdisciplinary Center for Plasma Mass Spectrometry at the University of
California at Davis. Cell lysates and platinum standards were introduced using a MicroMist
Nebulizer (Glass Expansion, Pocasset, MA) into a temperature controlled spray chamber. Plat-
inum standard solutions, were diluted from standardized platinum stock solutions (SPEX
CertiPrep, Metuchen, NJ) to concentrations from 0.01 to 300 ppb in 3% nitric acid (Fisher Sci-
entific, trace metal grade) in deionized water (Millipore). Cisplatin content, calculated from
platinum concentrations, was normalized to protein concentration (Bio-rad assay, Bio-rad.
Hercules, CA), and background readings, derived as platinum content of cells prior to cisplatin
incubation, were subtracted. Net cisplatin uptake (expressed as μg cisplatin/g protein) was first
determined as mol platinum per g protein and converted to weight of cisplatin by multiplying
by the ratio of molecular weights of cisplatin (300.1 g/mol) to platinum (195.1 g/mol).
Gene expression profiling by microarray analysis
Total RNA was isolated from spheroids using the Trizol reagent (Invitrogen, Carlsbad, CA).
Microarrays were processed at the Yale Center for Genome Analysis facility. RNA was frag-
mented and labeled with the Affymetrix GeneChip Whole Transcript Target Labeling Assay
and hybridized to the Affymetrix Human Gene 1.0 ST Arrays according to recommended Affy-
metrix protocols (Affymetrix, Santa Clara, CA). Signals were calculated by Robust Multichip
Analysis (RMA) using Expression Console software (Affymetrix, version 1.1). Genes with
low signals, defined as the lowest quartile in both cisplatin sensitive and resistant cells, were
excluded from further analysis. Raw and processed microarray data were deposited into the
NCBI Gene Expression Omnibus database (GSE45553).
Quantitative RT-PCR
Total RNA was isolated as described above and reverse-transcribed to cDNA as described pre-
viously [14]. Quantitative real-time PCR was performed using a Biorad iCycler (Hercules, CA)
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and PCR products were detected by EvaGreen-DNA binding (SsoFast EvaGreen Supermix,
Biorad). Gene expression relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was determined by the ΔΔCt method. Primer sequences are listed in S1 Table.
Bioinformatics and survival analysis
The Significance Analysis of Prognostic Signatures (SAPs) code and ovarian tumor datasets
were downloaded from dryad [15]. The OVCAR-8R derived datasets were added to the
MSigDB gene set list for SAPs analysis.
Hierarchical clustering was performed in Gene-E using Pearson correlation to calculate dis-
tances [16]. Survival analysis including the Cox Proportional Hazards model, Kaplan-Meier
analysis, and statistical tests including Student’s t-test were performed in R. Multiple hypothe-
sis corrections were performed using the qvalue package [17]. All The Cancer Genome Atlas
(TCGA) data were downloaded from the TCGA data portal using the published dataset. All
TCGA data include primary ovarian tumors only. The Australian Oncology Group microarray
data for ovarian tumors, GSE9891, was downloaded from GEO. Signals were normalized and
determined by RMA [18] and only primary tumors were considered.
Results
Selection of cisplatin resistant OVCAR-8 ovarian cancer cells
OVCAR-8 cells were chosen for this study because they readily form spheroids [13], have fea-
tures indicative of high-grade serous ovarian cancer [10], are mutant for p53 [19] and form
xenografts with HGSOC histology [20]. Therefore, we hypothesized OVCAR-8 cells would
provide a good cell line model to investigate cisplatin resistance mechanisms in spheroid con-
ditions. When initially derived and tested OVCAR-8 cells did not significantly express metal-
lothionein and were considered cisplatin sensitive relative to other patient derived cell lines
[21]. Selection of drug resistant lines from increasing drug concentrations remains a powerful
tool to gain insight into resistance mechanisms; however, little is understood with regard to
resistance mechanisms in the context of spheroid culture systems, which appear to model
tumors significantly better than monolayer culture [22].
Serial exposure of OVCAR-8 cells to sub-lethal concentrations of cisplatin resulted in signif-
icant, lasting changes in cisplatin resistance (Fig 1). In both monolayer and spheroid condi-
tions, cisplatin resistant cells, OVCAR-8R, showed a significant ~4-fold increase in the
cisplatin IC50. In monolayer cultures, resistant cells showed greater adhesion to the culture
vessel as indicated by the darker and flatter appearance under phase contrast (Fig 1C and 1D)
although no morphological differences could be determined for the spheroids themselves (Fig
1E and 1F). The proliferation rate of resistant cells was also diminished compared to sensitive
cells (data not shown). Cells remained resistant after growing in the absence of cisplatin for
multiple generations. We hypothesized that the differences between the resistant and sensitive
spheroids would better model mechanisms of resistance active in ovarian tumors compared to
monolayer culture. To begin to test this hypothesis, we examined the mRNA expression differ-
ences between the parental OVCAR-8 and the resistant OVCAR-8R cells in spheroids using
Affymetrix microarrays. OVCAR-8 and OVCAR-8R cells had strikingly different expression
profiles with 3,139 transcripts significantly differentially expressed (Fc>2, q<0.01) (S2 Table).
Eight genes were selected with a wide range of expression differences between the resistant
and sensitive cells to test in an orthogonal assay (Fig 2A and 2B). The differences in expression
between OVCAR-8 and OVCAR-8R for these genes were significantly correlated between
qPCR and microarray, supporting further analysis of the microarrays.
Cisplatin Resistance Spheroid Model
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OVCAR-8R cells sequester cisplatin
Drug transporters that mediate intracellular drug concentration have been investigated as driv-
ers of chemoresistance [23]. Many candidate cisplatin exporters, associated with cisplatin sen-
sitivity were significantly down-regulated, MDR1 (Fc> 3, q = 2e-5), hCTR1/SLC31A1 (Fc>2,
q = 2.6e-4) [24], ATP7A (Fc>2, q = 2e-5) [25] while others were up-regulated, MRP1/ABCC1
(Fc = 3, q = 1.7e-5) [26] and ABCA3 (Fc>2, q = 2e-4) [27], in the resistant line (S2 Table).
However, even though multiple pre-clinical models suggest the importance of MDR1 in cis-
platin resistance, MDR1 expression has only rarely been correlated with responses and survival
in ovarian cancer patients, even when considering multiple mechanisms of increasing MDR1
expression including promoter fusions [23].
The complicated mixture of differential expression of known cisplatin transporters did not
immediately suggest that cisplatin transport was responsible for the observed resistance. To
test whether drug transport and subsequent changes to intracellular concentration were driving
Fig 1. Selection of OVCAR-8 cells in increasing concentrations of cisplatin exposure leads to sustained resistance to cisplatin treatment. Cell
viability of cisplatin resistant and sensitive cells grown as monolayers (A) or spheroids (B), expressed as a percentage of untreated viability, following
exposure to varying concentrations of cisplatin for 96 h. Statistical comparisons were performed at each dose using a two-tailed Student’s t-test. Asterisks
(**, p<0.01; ***, p<0.001) indicate significant difference in viability between cisplatin-sensitive (dashed line) and resistant cells (solid line) at the same
cisplatin concentration (mean ± SE, n = 9). (C+D). Photomicrographs of cisplatin resistant (C) and sensitive (D) cells under phase contrast illumination.
Resistant cells display stronger adhesion to the substrate while sensitive cells do not. Photomicrographs of spheroids from resistant (E) and sensitive (F)
lines.
doi:10.1371/journal.pone.0151089.g001
Cisplatin Resistance Spheroid Model
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resistance in OVCAR-8R spheroids, we measured intracellular platinum concentration in the
spheroids using a cisplatin uptake assay by mass spectrometry. No difference in net uptake of
cisplatin in cisplatin-sensitive (25.2 ± 8.2 μg cisplatin/g protein) spheroids, compared to cis-
platin-resistant spheroids (26.5 ± 7.7 μg cisplatin/g protein) was observed. These observations
indicate that even though expression of many drug transporters was down-regulated in resis-
tant cells, the intracellular platinum concentration remained unaffected.
As OVCAR-8R spheroids did not demonstrate reduced intracellular platinum concentra-
tions, other potential resistant pathways were evaluated. To handle intracellular platinum
concentrations, sequestration can be mediated by platinum binding proteins including Gluta-
thione-S Transferases and metallothioneins [5]. Large increases in expression of genes that
bind cisplatin such as metallothioneins (MT2A and MT1E) were observed, indicating that the
concept cisplatin may be sequestered in these cells. The metallothionein I and II isoforms have
increased expression between 3-fold to 7-fold in OVCAR-8R cells, and MT1E was among the
top genes up-regulated (Fc = 47, q = 3e-7) compared to OVCAR-8 cells. Higher expression of
metallothioneins is a known mechanism of cisplatin resistance and increased expression in
OVCAR-8R cells may drive platinum sequestration and drug resistance [4].
To identify pathways that may be mediating resistance, gene set enrichment analysis,
(GSEA), was performed [28]. DNA repair pathways can be up-regulated in resistant cells and
have been associated with patient survival [29]. The nucleotide excision repair pathway was
not significantly differentially expressed (S3 Table). GSEA revealed that none of the major
DNA repair pathways were significantly enriched in the OVCAR-8R spheroids (S3 Table).
GSEA did identify numerous differentially expressed pathways (S3 Table), consistent with
increased resistance including apoptosis regulation (Apoptosis Hallmark gene set NES = 1.9,
FDR = 2e-4), including the apoptosis inhibitors, BIRC3 and BCL2L1 (S2 Table), and the
inflammatory response Hallmark gene set (NES = 2.3, FDR< 1e-4), characterized by increased
expression of IL6, IL18, IL8, IL1A, and TNF (S2 Table).
Fig 2. Differentially expressed transcripts between OVCAR-8R and OVCAR-8 spheroids are correlated betweenmicroarray and qPCR assays.
Genes in the microarray dataset with differences in expression between sensitive and resistant ovarian cancer spheroids. (A) qPCR and microarray
expression levels correlate. qPCR relative expression was calculated relative to GAPDH. Microarray scores are RMA. Trend line was determined by linear
regression (r2 = 0.71, p = 0.009). (B) The fold changes for the selected transcripts.
doi:10.1371/journal.pone.0151089.g002
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Reactome nucleotide metabolism gene set (NES = 1.4, FDR = 0.18) including NT5E,
recently linked to cisplatin resistance [30] (S2 Table) was strongly up-regulated OVCAR-8R
spheroids. Together, these observations indicate that multiple pathways are dysregulated con-
tributing to the increased resistance of the OVCAR-8R spheroids.
Resistant OVCAR-8R cells are more mesenchymal
In order to test the hypothesis that the OVCAR-8R cells are more mesenchymal compared to
OVCAR-8 cells, we evaluated whether the global gene expression program was indicative of a
more mesenchymal phenotype. Mesenchymal cancer cells can be identified by examination of
expression signatures indicative of mesenchymal states [31]. Epithelial-mesenchymal transi-
tion (EMT) status in ovarian tumors is typically associated with more aggressive tumors and
shorter survival [32, 33]. The EMT hallmark gene set was the top-ranked cancer hallmark gene
set when comparing OVCAR-8R and OVCAR-8 spheroids by GSEA (Fig 3A). Common mes-
enchymal markers including MMP1, CD44, TGFBI, FN1, and vimentin had significantly
higher expression in OVCAR-8R cells (Fig 3B). Dr. Brugge and colleagues recently reported
ovarian cancer cells that were more mesenchymal were more invasive and correlated with poor
outcome [33]. We observed significant overlap between the 3,139 differentially expressed
resistant genes and the EMT signature proposed by Taube et al. (2010) (Overlap = 91 genes,
P = 0.0001). These 91 EMT genes were strongly differentially expressed between OVCAR-8
and OVCAR-8R spheroids (Fig 3C). However, none of the major EMT transcription factors
(SNAI1, SNAI2, TWIST1, ZEB1, or ZEB2) were significantly up-regulated in OVCAR-8R cells.
In fact, only ZEB1 was modestly differentially expressed and it was 2-fold down-regulated in
the resistant cells. Of special note, the expression of these factors was already high in OVCAR-
8 spheroids, likely from the adaptation to spheroid cultures, which has been reported to
increase expression of mesenchymal markers [33].
Alternatively, EMT could be driven by YAP1, another transcriptional driver that increases
cancer stemness and EMT in multiple systems [34]. YAP1 is expressed 3 fold higher in
OVCAR-8R spheroids (Fc = 1.5, q = 1e-5) and a YAP1 gene expression program is up-regu-
lated as well (YAP1_up gene set [35], NES = 1.75, FDR = 0.002). These observations indicate a
potential mechanism of EMT control, independent of expression changes of more classical
EMT transcription factors, as YAP1 has recently been reported to drive EMT in multiple sys-
tems including ovarian cancer [34, 36–38]. OVCAR-8 cells are KRAS mutant and activation of
YAP1 may be working with KRAS activation to drive resistance [37], indicating that inhibition
of both KRAS and YAP1 could overcome resistance in this model.
Resistance gene expression signature is associated with survival
An increased mesenchymal state has been associated with shorter survival in ovarian cancer
[33]. In order to determine if mechanisms of resistance captured by gene expression in
OVCAR-8R spheroids were relevant to ovarian tumors in patients, we pursued two approaches
to examine gene expression in ovarian tumors. We tested if the cisplatin resistant gene sets
were significantly associated with poor survival, relative to random gene sets and gene sets
fromMsigDB using the SAPS algorithm [39]. The SAPS approach considers a whole gene set,
similar to GSEA, such that different combinations of transcripts may be biased in any one sam-
ple and the cumulative bias across all samples leads to the enrichment scores. The SAPS gene
set approach was applied to 1735 ovarian cancer patients from twelve ovarian tumor datasets
with available overall survival data as described [40]. SAPS compares each gene set to random
gene sets of equivalent size (p_random, Fig 4). We examined two gene sets with the largest fold
changes between the OVCAR-8R and OVCAR-8 with q<0.01 at Fc>3 and>4 and compared
Cisplatin Resistance Spheroid Model
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the resistance gene set to those from the Kegg, Reactome, BioCarta, and Gene Ontology data-
bases. Fig 4 shows that these two gene sets rank among the highest of the 5373 gene sets tested,
with q-values of 0.002 for Fc>3 and 0.003 for Fc>4, near the maximum obtainable by the
algorithm. Fig 4A shows the strong enrichment of the resistance gene sets across all the ovarian
tumors evaluated. As a control, we list the HOX13_01 gene set, which was reported to be one
of the most significantly associated with survival in ovarian cancer [40]. These observations
indicate that the most differentially expressed genes in the OVCAR-8R spheroids significantly
Fig 3. Cisplatin resistance genes significantly overlap with genes associated with the mesenchymal state. (A) GSEA enrichment shows that the EMT
hallmark gene set is significantly biased towards OVCAR-8R spheroids compared to OVCAR-8. (B) Key mesenchymal markers are significantly up-regulated
in OVCAR-8R compared to OVCAR-8 spheroids. (C) The Taube EMT signature separates the OVCAR-8R and OVCAR-8 spheroids by hierarchical
clustering using Gene-E with Pearson correlation calculated distances. Each row represents a gene. R is the OVCAR-8R and S is the parental OVCAR-8
spheroids. Red indicates higher risk, blue indicates lower risk.
doi:10.1371/journal.pone.0151089.g003
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identified patients with more aggressive and/or chemoresistant tumors leading to shorter over-
all survival.
To assess if a defined gene expression signature can be derived from the list of differentially
expressed transcripts that is associated with patient survival, we identified a 17 gene expression
signature that separated OVCAR-8 and OVCAR-8R cells (Fig 5A) and separated high and low
risk patients in 3 independent datasets (Fig 5B). These 17 transcripts, selected from the 3,139
resistant gene expression list, were significantly associated with survival in all three indepen-
dent datasets (Table 1). These observations suggest that features of the sensitive and resistant
cells are indicative of tumor behavior in patients.
Discussion
We developed a new spheroid model of drug resistance and provided evidence supporting its
utility as a model for HGSOC tumors. We applied genome-wide expression profiling to gain
insight into potential resistance mechanisms in the spheroids and examined which pathways
may be relevant to patient tumors. In this model, resistance was not due to changes in drug
transport or DNA repair, but rather to sequestration in combination with increased expression
of anti-apoptosis pathways, cytokines, and an increased mesenchymal expression profile.
Importantly, the changes adapted by the resistant cells in the expression profile identified
patients with shorter survival and higher likelihood of relapse. We conclude that multiple
Fig 4. Differentially expressed transcripts are associated with survival acrossmultiple ovarian cancer datasets. (A) SAPS analysis across 1735
ovarian tumor datasets suggests that both the Fc3 and Fc4 resistance transcript lists are significantly associated with shorter survival. (B) The Fc3 and Fc4
resistance gene sets were strongly enriched for shorter survival in the top 5% of all 5357 gene sets tested. Statistics for the resistance and representative
strongly enriched gene sets are shown. The HOX13_01 gene set is shown as a positive control to compare the statistics.
doi:10.1371/journal.pone.0151089.g004
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mechanisms contribute to the cisplatin resistance of OVCAR-8R spheroids that are relevant to
patients.
Previous in vitromodels of selected cisplatin resistance in ovarian cancer cell lines revealed
a plethora of resistance mechanisms [6], of which sequestration and platinum inactivation are
Fig 5. A 17 cisplatin resistance gene expression signature was associated with shorter survival across three independent datasets and
distinguishes OVCAR-8R fromOVCAR-8 cells.Genes up-regulated in OVCAR-8R spheroids are expressed higher in patients with shorter survival and
vice-versa. (A) Hierarchical clustering with Pearson correlation distances separates high and low expression in OVCAR-8R and OVCAR-8 spheroids.
Hierarchical clustering was performed using Gene-E software [16]. (B) Overall survival curves for the three indicated datasets. Only patients with survival
data up to 5 years were considered. The number of patients (n), median survival (med), and the p-value from a log-rank test are indicated. The red line
indicates high risk and the black line represents low risk patients.
doi:10.1371/journal.pone.0151089.g005
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examples [21, 41]. To determine how the OVCAR-8R spheroid resistance model compares to
previously described cisplatin resistance models, we compared the gene expression changes to
the A2780 resistance model in the GSE15709 [42] and GSE28648 [43] datasets. We found just
39 genes were differentially expressed across all 3 datasets (data not shown). We hypothesized
that these 39 genes would be associated with survival and chemoresponse in patients. However,
no significant association with survival was observed (data not shown). These findings indicate
that the heterogeneity of the cell line models makes it challenging to connect gene expression
signatures derived from such different conditions in this heterogeneous disease. This could be
due to the strikingly different genetic backgrounds of these cell lines or because of the differ-
ences in monolayer vs. spheroid culture conditions. Phenotypic and genetic analysis of pre-
clinical models, including established cell lines, has led to sometimes-conflicting interpreta-
tions of the validity of certain models [7]. The extreme genetic heterogeneity of ovarian tumors
warrants continued development of pre-clinical models to capture the range of resistance
mechanisms in various genetic backgrounds.
We specifically tested if resistance is associated with decreased platinum concentrations in
the resistant cells and did not observe a significant difference in intracellular cisplatin concen-
trations. The gene expression data and platinum uptake assay were consistent with cisplatin
resistance being caused by increased sequestration of platinum, through up-regulation of
metallothionein and other sulfur rich proteins. Consistent with sequestration, metallothionein
I and II isoforms were up-regulated between 3-fold to 7-fold in OVCAR-8R cells, and metal-
lothionein-1E was among the top genes up-regulated (47-fold) compared to parental OVCAR-
8 cells. Higher expression of metallothioneins is a known mechanism of cisplatin resistance
and their increased expression in OVCAR-8R cells is likely contributing to the observed resis-
tance [4]. Therefore, the role of transporters in this OVCAR-8R spheroid model are different
Table 1. The 17 transcripts constituting the resistance survival expression signature.
Gene
Symbol
Gene Name Expression Levels in High
Risk Patients
APOE apolipoprotein E High
BTG2 BTG family, member 2 Low
CTSA cathepsin A High
EIF1AX eukaryotic translation initiation factor 1A, X-linked Low
FLNC ﬁlamin C, gamma (actin binding protein 280) High
GNA12 guanine nucleotide binding protein (G protein) alpha 12 High
IGFBP4 insulin-like growth factor binding protein 4 High
LGI2 leucine-rich repeat LGI family, member 2 High
MEIS1 Meis homeobox 1 Low
NLGN1 neuroligin 1 Low
OLFML3 olfactomedin-like 3 High
PCOLCE2 procollagen C-endopeptidase enhancer 2 High
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-
dependent)
Low
PTH2R parathyroid hormone 2 receptor High
RPRM reprimo, TP53 dependent G2 arrest mediator candidate Low
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1
High
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains
proteoglycan (testican) 1
High
doi:10.1371/journal.pone.0151089.t001
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than the OVCAR-8 derived cisplatin resistant NCI/ADR-RES line, characterized by high
MDR1 expression [44].
The mesenchymal nature of ovarian cancer cells is most often associated with more drug
resistant tumors and shorter survival [32, 33, 45, 46]. OVCAR-8 cells are an epithelial cell
and 3D culture drives the mesenchymal state [47]. We observed increased expression in
genes associated with epithelial—mesenchymal transition (EMT), such as YAP1, vimentin,
fibronectin, collagen type 1 alpha 1, and P-cadherin expression [48]. OVCAR8 cells are
reported to have relatively high YAP1 expression [49]. We observed changes in growth factor
genes associated with EMT, such as transforming growth factor (TGF-β), epidermal growth
factor (EGF), and fibroblast growth factor (FGF). The global gene expression pattern further
supports the increased mesenchymal state of the OVCAR-8R spheroids. Together, these
observations indicate that the OVCAR-8R spheroids model more mesenchymal, drug resis-
tant tumors.
Our observations indicate that the OVCAR-8 spheroids represent a good model to examine
cisplatin resistance in vitro. Similar to ovarian tumors, multiple mechanisms appear to contrib-
ute to resistance and the differentially expressed genes in the resistant cells correlate with poor
outcomes in patients. These changes in gene expression were long-lasting responses as resis-
tance was maintained after extensive culture in the absence of platinum. This in vitromodel
reflects similar cisplatin resistance mechanisms as those found in patients and will be useful for
further physiological characterization of the resistance and investigation of methods for killing
drug resistant cancer cells. We cannot conclude that all the observed changes are only observed
in the spheroid form of the cells and not in the monolayer. Here, we focused on the spheroids
and future efforts may evaluate differences in monolayer cultures.
A limitation of our study is that we only analyzed one cell line. Despite this limitation, this
spheroid model is relevant to ovarian tumors as indicated by the common gene expression
changes observed in the model and in ovarian tumors. The observation of the increased expres-
sion of many mesenchymal markers, a global gene expression profile associated with survival
using a global analysis, SAPS, as well as the derivation of a specific 17 gene expression signa-
ture, all support the utility of this spheroid model to investigate mechanisms relevant to
patients.
In summary, these observations indicate that the mechanisms of resistance in the OVCAR-
8R cell line model are relevant to ovarian cancer patients, and support further investigation
into the role of these genes in the development of resistance in ovarian cancer. This study of a
spheroid model of ovarian cancer provides a foundation to gain new insights into cisplatin
resistance in an in vitromodel.
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